Inhibition of Borna disease virus replication by ribavirin.
The guanosine analogue ribavirin was tested for antiviral activity in two neural cell lines, human oligodendrocytes and rat glia, against Borna disease virus (BDV) strains V and He/80. Ribavirin treatment resulted in lower levels of virus and viral transcripts within 12 h. Addition of guanosine but not adenosine resulted in a profound reduction of the ribavirin effect. Ribavirin appears to be an effective antiviral agent for treatment of BDV infection in vitro. A likely mechanism for its activity is reduction of the intracellular GTP pool, resulting in inhibition of transcription and capping of BDV mRNAs.
Jordan
I
I
Laboratory for the Study of Emerging Diseases, Department of Neurology, University of California, Irvine, California 92697-4292, USA.
Briese
T
T
Averett
D R
DR
Lipkin
W I
WI
D000241:Adenosine / Q000378:metabolism; D000818:Animals; D000998:Antiviral Agents / Q000378:metabolism / Q000494:pharmacology*; D001891:Borna disease virus / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D002460:Cell Line; D006151:Guanosine / Q000378:metabolism; D006160:Guanosine Triphosphate / Q000378:metabolism; D006801:Humans; D009457:Neuroglia; D009836:Oligodendroglia / Q000166:cytology; D051381:Rats; D012254:Ribavirin / Q000378:metabolism / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D006151:Guanosine; D012254:Ribavirin; D006160:Guanosine Triphosphate; D000241:Adenosine